4-（2-乙氧基乙氧基）哌啶 | 70978-93-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-（2-乙氧基乙氧基）哌啶
• 英文名称: 4-(2-ethoxyethoxy)piperidine
• CAS: 70978-93-7
• 化学式: C₉H₁₉NO₂
• mdl: MFCD08687707
• 分子量: 173.255
• InChiKey: YUAFBJXCTHYOSJ-UHFFFAOYSA-N

物化性质

• 沸点：
  239.6±30.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,6-dichloro-4-amino-7,8-dimethoxyquinazoline 、 4-（2-乙氧基乙氧基）哌啶 在 盐酸 、 三乙胺 作用下， 以 乙醇 、 正丁醇 为溶剂， 生成 2-[4-(2-Ethoxyethoxy)piperidin-1-yl]-4-amino-6-chloro-7,8-dimethoxyquinazoline hydrochloride
  参考文献：
  名称：

  Alkoxy-substituted-6-chloro-quinazoline-2,4-diones

  摘要：

  2,4-二氨基喹唑啉的化学式为##STR1##，其中Y.sup.1为氢或氯，Y.sup.2为OR，Y.sup.3为氢或OR，当Y.sup.1为氢时，Y.sup.3为OR，当Y.sup.1为氯时，Y.sup.3为氢或OR，以及其药用盐；R代表一个具有一至三个碳原子的烷基基团；单独取R.sup.1和R.sup.2分别为氢、具有一至五个碳原子的烷基、具有三至八个碳原子的环烷基、具有三至五个碳原子的烯基或炔基，或具有两至五个碳原子的羟基取代的烷基，当与它们连接的氮原子一起时，R.sup.1和R.sup.2形成一个取代或未取代的杂环基团，该基团可选地含有一个氧原子、硫原子或第二个氮原子作为环成员；它们作为降压药剂的用途，含有它们的药物组合物以及它们生产的中间体。

  公开号：

  US04287341A1
• 作为产物：
  描述：

  N-乙酰基-4-羟基哌啶 、 2-溴乙基乙基醚 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 paraffin 为溶剂， 以24%的产率得到4-（2-乙氧基乙氧基）哌啶
  参考文献：
  名称：

  2,4-Diamino-6,7-dimethoxyquinazolines. 4. 2-[4-(Substituted oxyethoxy)piperidino] derivatives as .alpha.1-adrenoceptor antagonists and antihypertensive agents

  摘要：

  A series of 4-amino-6,7-dimethoxy-2-[4-(substituted oxyethoxy)piperidino] quinazoline derivatives (2) was synthesized and evaluated for alpha-adrenoceptor affinity and antihypertensive activity. Most compounds showed binding affinities within the nanomolar range for alpha 1-receptors, although 25 and 26 showed enhanced potency (Ki, ca. 1.5 X 10(-10) M), equivalent to that of prazosin. Series 2 also displaced [3H]clonidine from alpha 2-adrenoceptors, but at relatively high doses of 10(-6) M, and selectivity for alpha 1 sites still predominated. In a rabbit pulmonary artery preparation, 12, 16, and 25 were potent antagonists of the alpha 1-mediated, postjunctional vasoconstrictor activity of norepinephrine with no effect at the prejunctional alpha 2 sites which modulate transmitter release. Physicochemical measurements gave a pKa of 7.63 +/- 0.10 for 12, and N-1 protonation will be favored (60%) at physiological pH to provide the alpha 1-adrenoceptor pharmacophore, 28. Antihypertensive activity of series 2 was evaluated following oral administration to spontaneously hypertensive rats, and blood pressure was measured after 1 and 6 h. Compounds 12, 13, 16, 23, and 37 displayed moderate efficacy and duration of action in lowering blood pressure, but the plasma half-life (ca. 2 h) of 16 in dogs was not compatible with potential once-daily administration in humans.

  DOI：

  10.1021/jm00398a006

文献信息

• Antihypertensive
  申请人：Pfizer Inc.

  公开号：US04237138A1

  公开（公告）日：1980-12-02

  Regulators of the cardiovascular system and, in particular, in the treatment of hypertension having the formula ##STR1## pharmaceutically-acceptable bioprecursors thereof, and the pharmaceutically-acceptable acid addition salts thereof; wherein each of R.sup.1 and R.sup.2 is C.sub.1-4 alkyl or --CH.sub.2 CF.sub.3 ; alk is ethylene, monophenyl substituted ethylene, mono- and dimethyl substituted ethylene or monophenylmonomethyl substituted ethylene; and R.sup.3 is hydrogen, C.sub.1-4 alkyl, C.sub.3 -C.sub.6 cycloalkyl; phenyl or substituted phenyl; and methods for their preparation.

  心血管系统的调节剂，特别是治疗高血压的化学式为##STR1##的药用可接受的生物前体，以及其药用可接受的酸盐；其中R.sup.1和R.sup.2中的每一个是C.sub.1-4烷基或--CH.sub.2 CF.sub.3；alk是乙烯，单苯基取代的乙烯，单甲基和双甲基取代的乙烯或单苯基单甲基取代的乙烯；而R.sup.3是氢，C.sub.1-4烷基，C.sub.3-C.sub.6环烷基；苯基或取代苯基；以及它们的制备方法。
• [EN] 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE 4-AMINOPYRIDO[2,3-D]PYRIMIDINE A DISUBSTITUTION 5,7
  申请人：ABBOTT LAB

  公开号：WO2000023444A1

  公开（公告）日：2000-04-27

  A method of inhibiting adenosine kinase by administering one of more compounds of formula (I), wherein R?1, R2, R3 and R4¿ are defined, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, and a method of treating cerebral ischemia, epilepsy, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, a process for preparing said compounds, and compounds having the above formula wherein R?1, R2, R3 and R4¿ are separately defined.

  一种通过给予式(I)中的一个或多个化合物来抑制腺苷激酶的方法，其中R1、R2、R3和R4被定义，以及包含上述化合物的治疗有效量与药学可接受载体组合的制药组合物，以及一种治疗哺乳动物的脑缺血、癫痫、疼痛感知、炎症和败血症的方法，包括给予哺乳动物上述化合物的治疗有效量，制备上述化合物的方法以及具有上述式中R1、R2、R3和R4分别被定义的化合物。
• Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
  申请人：Pfizer Inc.

  公开号：US04377581A1

  公开（公告）日：1983-03-22

  2,4-Diaminoquinazolines of the formula ##STR1## wherein Y.sup.1 is hydrogen or chloro, Y.sup.2 is OR, Y.sup.3 is hydrogen or OR such than when Y.sup.1 is hydrogen, Y.sup.3 is OR and when Y.sup.1 is chloro, Y.sup.3 is hydrogen or OR, and the pharmaceutically acceptable salts thereof; R represents an alkyl group having from one to three carbon atoms; taken separately, R.sup.1 and R.sup.2 are each hydrogen, alkyl having from one to five carbon atoms, cycloalkyl having from three to eight carbon atoms, alkenyl or alkynyl each having from three to five carbon atoms or hydroxy substituted alkyl having from two to five carbon atoms, when taken together with the nitrogen atom to which they are attached R.sup.1 and R.sup.2 form a substituted or unsubstituted heterocyclic group optionally containing an atom of oxygen, sulfur or a second atom of nitrogen as a ring member; their use as antihypertensive agents, pharmaceutical compositions containing them and intermediates for their production.

  该专利描述了式子##STR1##中Y.sup.1是氢或氯，Y.sup.2是OR，Y.sup.3是氢或OR，当Y.sup.1是氢时，Y.sup.3是OR，当Y.sup.1是氯时，Y.sup.3是氢或OR。其中R代表一个由一个到三个碳原子组成的烷基；R.sup.1和R.sup.2分别为氢、由一个到五个碳原子组成的烷基、由三到八个碳原子组成的环烷基、由三到五个碳原子组成的烯基或炔基或在有机取代的情况下，为由两个到五个碳原子组成的羟基取代的烷基。当它们与它们所连接的氮原子一起取代时，R.sup.1和R.sup.2形成一个取代或未取代的杂环基，该杂环基可以选择性地包含一个氧原子、硫原子或第二个氮原子作为环成员。该专利还涉及这些化合物作为降压剂的用途，包含它们的制药组合物以及它们的中间体的生产。
• Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them
  申请人：PFIZER INC.

  公开号：EP0028473A1

  公开（公告）日：1981-05-13

  2,4-Diaminoquinazolinesoftheformula: and the pharmaceutically acceptable salts thereof are disclosed and claimed as novel compounds having useful antihypertensive activity wherein: Y' is hydrogen or chloro, Y2 is OR and Y' is hydrogen or OR, such that when Y' is hydrogen, Y3 is OR and when Y' is chloro, Y3 is hydrogen or OR; R represents an alkyl group having from one to three carbon atoms; when taken separately, R1 and R2 are each hydrogen, alkyl having from one to five carbon atoms, cycloalkyl having from three to eight carbon atoms, alkenyl or alkynyl each having from three to five carbon atoms or hydroxy substituted alkyl having from two to five carbon atoms; when taken together with the nitrogen atom to which they are attached, R and R2 form any one of a number of specified substituted or unsubstituted heterocyclic groups optionally containing also an atom of oxygen, sulfur or a second atom of nitrogen as a ring member. Also disclosed and claimed are pharmaceutical compositions containing such compounds, and novel intermediates for their production, having the formulae: and

  2,4-Diaminoquinazolinesoftheformula： 及其药学上可接受的盐类公开并声称是具有有用的抗高血压活性的新型化合物，其中：Y'是氢或氯，Y2是OR，Y'是氢或OR，这样，当Y'是氢时，Y3是OR，当Y'是氯时，Y3是氢或OR；R代表具有1至3个碳原子的烷基；当单独使用时，R1和R2各自是氢、具有1至5个碳原子的烷基、具有3至8个碳原子的环烷基、各自具有3至5个碳原子的烯基或炔基或具有2至5个碳原子的羟基取代的烷基；当 R 和 R2 与它们所连接的氮原子结合在一起时，R 和 R2 形成若干指定的取代或未取代的杂环基团中的任一个，这些杂环基团还可选择含有一个氧原子、硫原子或第二个氮原子作为环成员。本发明还公开了含有此类化合物的药物组合物，以及用于生产此类化合物的新型中间体，其结构式为 和
• PYRAZOLOQUINOLINE COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：EP2615089A1

  公开（公告）日：2013-07-17

  [Problem] Provided is a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, bladder/urethral diseases, and the like. [Means for Solution] The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, bladder/urethral diseases, and the like, and thus, have found that a pyrazoloquinoline compound has a PDE9-inhibiting action, thereby completing the present invention. The pyrazoloquinoline compound of the present invention has a PDE9-inhibiting action and can be used as an agent for preventing and/or treating storage dysfunction, voiding dysfunction, bladder/urethral diseases, and the like.

  问题 本发明提供了一种化合物，该化合物具有 PDE9 抑制作用，可用作治疗和/或预防储藏功能障碍、排尿功能障碍、膀胱/尿道疾病等药物的活性成分。 [解决方法］ 本发明人研究了一种具有 PDE9 抑制作用且可作为治疗和/或预防储藏功能障碍、排尿功能障碍、膀胱/尿道疾病等药物的活性成分的化合物，并因此发现一种吡唑喹啉化合物具有 PDE9 抑制作用，从而完成了本发明。本发明的吡唑喹啉化合物具有 PDE9 抑制作用，可用作预防和/或治疗储藏功能障碍、排尿功能障碍、膀胱/尿道疾病等的药物。